BioMed X Launches Women’s Health R&D Accelerator

BioMed X has launched XFem Labs, a new Women’s Health R&D Accelerator in Heidelberg. The initiative, which is supported by the Gates Foundation, intends to establish a world-class women’s health innovation hub that advances early-stage research into scalable solutions for women in need around the world.

The first project at the new XFem Labs accelerator in Heidelberg is entitled “New Strategies for Female-Controlled Non-Hormonal Contraception.” Despite the availability of various contraceptive methods, 257 million women worldwide still face significant barriers to access. Current hormonal contraceptives are often associated with side effects, such as changes in bleeding patterns, resulting in high discontinuation rates. Non-hormonal, female-controlled alternatives remain limited and often challenging, hence there is an urgent need for new options.

The first XFem Labs call for application invites proposals that explore new biological targets, molecular mechanisms, or delivery modalities for continuous and/or on-demand non-hormonal contraception. Selected researchers will participate in a boot camp at BioMed X, resulting in the incubation of a new research team based In Heidelberg.

“Our joint goal with the Gates Foundation is to create a significant impact on the lives and health of women world-wide,” said Dr. Christian Tidona, CEO of BioMed X. “Together with an international network of top experts and key opinion leaders, we will jointly build and mentor new outstanding research teams who will strive to solve some of the most pressing challenges in women’s health.”

Researchers interested in becoming part of this new research group can submit a project proposal via the BioMed X Career Space before December 7, 2025.